Get started
Author

Arim Seo

ORCID: 0009-0004-8434-7681
Observed ORCID: 0009-0004-8434-7681
OpenAlex ID: A5078879335
Arc complexes, sphere complexes, and Goeritz groups
2016 · Sangbum Cho, Yuya Koda, et al. · The Michigan Mathematical Journal · 9
PDF
Arc distance equals level number
2009 · Sangbum Cho, Darryl McCullough, et al. · Proceedings of the American Mathematical Society · 5
PDF
ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al. · Molecular Cancer Therapeutics · 1
Data from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Figure 3 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Figure S5 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Table S3 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Table S2 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Figure 5 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Table S4 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Figure 2 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Figure S6 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Figure 4 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Figure S16 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Figure S14 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Figure S2 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Figure 1 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Figure 6 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Figure S15 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Figure S3 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Figure S12 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Table S1 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Figure S13 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Figure S8 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Figure S1 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Works count: 32
Citation count: 15
H-index: 2
I10-index:
Year
Topic
Type